These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20473853)

  • 21. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
    Kopec JA; Goel V; Bunting PS; Neuman J; Sayre EC; Warde P; Levers P; Fleshner N
    J Urol; 2005 Aug; 174(2):495-9; discussion 499. PubMed ID: 16006879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen screening and mortality from prostate cancer.
    Marcella SW; Rhoads GG; Carson JL; Merlino F; Wilcox H
    J Gen Intern Med; 2008 Mar; 23(3):248-53. PubMed ID: 18172740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen testing of older men.
    Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
    J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes mellitus and the risk of prostate cancer in Italy.
    Tavani A; Gallus S; Bertuzzi M; Dal Maso L; Zucchetto A; Negri E; Franceschi S; Ramazzotti V; Montella M; La Vecchia C
    Eur Urol; 2005 Mar; 47(3):313-7; discussion 317. PubMed ID: 15716192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer.
    Miller EA; Pinsky PF; Pierre-Victor D
    Cancer Causes Control; 2018 Oct; 29(10):907-914. PubMed ID: 30094676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
    Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
    Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.
    Gann PH; Hennekens CH; Stampfer MJ
    JAMA; 1995 Jan; 273(4):289-94. PubMed ID: 7529341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
    Agalliu I; Weiss NS; Lin DW; Stanford JL
    Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing level of prostate-specific antigen and prostate cancer risk factors among 193 men examined in screening procedure.
    Opalińska E; Michalak A; Stoma F; Latalski M; Goniewicz M
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):57-63. PubMed ID: 15323167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
    BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
    Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10 ng/mL.
    Fukushima H; Masuda H; Kawakami S; Ito M; Sakura M; Numao N; Koga F; Saito K; Fujii Y; Yamamoto S; Yonese J; Fukui I; Kihara K
    Urology; 2012 Jun; 79(6):1329-34. PubMed ID: 22656412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
    Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
    Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland.
    Auvinen A; Tammela T; Stenman UH; Uusi-Erkkilä I; Leinonen J; Schröder FH; Hakama M
    Br J Cancer; 1996 Aug; 74(4):568-72. PubMed ID: 8761371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
    Aus G; Damber JE; Khatami A; Lilja H; Stranne J; Hugosson J
    Arch Intern Med; 2005 Sep; 165(16):1857-61. PubMed ID: 16157829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study.
    Oliver SE; Gunnell D; Donovan J; Peters TJ; Persad R; Gillatt D; Pearce A; Neal DE; Hamdy FC; Holly J
    Int J Cancer; 2004 Mar; 108(6):887-92. PubMed ID: 14712493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.